AIDS Therapies

Two-Year Resistance Data Presented For Lopinavir/Ritonavir

Published in AIDS Weekly, January 7th, 2002

Data presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago shows drug resistance has yet to emerge in naive patients who have been taking Kaletra for 96 weeks.

The study of patients new to HIV therapy showed that of those who experienced viral rebound (HIV RNA >400 copies/mL), no patient (0/40) treated with a Kaletra-based regimen was found to have protease inhibitor-resistant HIV by genotypic analysis, compared to 33% (28/84) of patients treated with a nelfinavir-based regimen. These findings for Kaletra also were confirmed by phenotypic analysis in 37 patients for whom phenotype was available.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry